Drug-related pneumonitis induced by osimertinib as firstline treatment for EGFR-positive non-small cell lung cancer: A real-world setting

被引：0

作者：

Sato, Y. ^{[1
]}

Sumikawa, H. ^{[2
]}

Shibaki, R. ^{[3
]}

Morimoto, T. ^{[4
]}

Sakata, Y. ^{[5
]}

Oya, Y. ^{[6
]}

Tamiya, M. ^{[7
]}

Suzuki, H. ^{[8
]}

Matsumoto, H. ^{[9
]}

Kijima, T. ^{[10
]}

Hashimoto, K. ^{[11
]}

Kobe, H. ^{[12
]}

Hino, A. ^{[13
]}

Inaba, M. ^{[14
]}

Tsukita, Y. ^{[15
]}

Ikeda, H. ^{[16
]}

Arai, D. ^{[17
]}

Maruyama, H. ^{[18
]}

Sakata, S. ^{[19
]}

Fujimoto, D. ^{[3
]}

机构：

[1] Kobe City Med Ctr Gen Hosp, Dept Resp Med, Kobe, Hyogo, Japan

[2] Natl Hosp Org, Dept Radiol, Kinki Chuo Chest Med Ctr, Sakai, Osaka, Japan

[3] Wakayama Med Univ, Internal Med 3, Wakayama, Japan

[4] Hyogo Coll Med, Dept Clin Epidemiol, Nishinomiya, Hyogo, Japan

[5] Saiseikai Kumamoto Hosp, Div Resp Med, Kumamoto, Japan

[6] Aichi Canc Ctr Hosp, Thorac Oncol, Nagoya, Aichi, Japan

[7] Osaka Int Canc Inst, Thorac Oncol, Osaka, Japan

[8] Osaka Prefectural Habikino Hosp, Dept Resp Med, Habikino, Japan

[9] Hyogo Kenritsu Amagasaki Hosp, Resp Med, Amagasaki, Hyogo, Japan

[10] Hyogo Coll Med, Resp Med & Hematol, Nishinomiya, Hyogo, Japan

[11] Toneyama Hosp, Dept Thorac Oncol, Natl Hosp Org, Toyonaka, Osaka, Japan

[12] Kurashiki Cent Hosp, Dept Resp Med, Kurashiki, Okayama, Japan

[13] Chiba Univ, Sch Med, Dept Respirol, Chiba, Japan

[14] Kumamoto City Hosp, Dept Resp Med, Kumamoto, Japan

[15] Tohoku Univ, Resp Med, Sendai, Miyagi, Japan

[16] Kimitsu Chuo Hosp, Dept Resp Med, Kisarazu, Japan

[17] Saiseikai Utsunomiya Hosp, Pulm Div, Dept Internal Med, Utsunomiya, Tochigi, Japan

[18] Kumamoto Rosai Hosp, Dept Resp Med, Yatsushiro, Japan

[19] Kumamoto Univ, Resp Med, Kumamoto, Japan

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1103P

引用

页码：S1055 / S1056

页数：2

共 50 条

[31] Exposure-Response Analysis of Osimertinib in EGFR Mutation Positive Non-Small Cell Lung Cancer Patients in a Real-Life Setting
Boosman, Rene J.
Jebbink, Merel
Veldhuis, Wouter B.
Groenland, Stefanie L.
van Veggel, Bianca A. M. H.
Moeskops, Pim
de Langen, Adrianus J.
Beijnen, Jos H.
Smit, Egbert F.
Huitema, Alwin D. R.
Steeghs, Neeltje
[J]. PHARMACEUTICAL RESEARCH, 2022, 39 (10) : 2507 - 2514
[32] Comment on: 'Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer'
Inagaki, Yuji
Tamiya, Akihiro
[J]. LUNG CANCER, 2020, 148 : 179 - 180
[33] Patient Age and EGFR-positive Non-small Cell Lung Cancer: A Multicenter Retrospective Study
Maezawa, Yosuke
Taguchi, Manato
Kawakami, Takeshi
Inui, Toshihide
Okauchi, Shinichiro
Numata, Takeshi
Shiozawa, Toshihiro
Miyazaki, Kunihiko
Nakamura, Ryota
Iguchi, Kesato
Endo, Takeo
Sakamoto, Tohru
Satoh, Hiroaki
Hizawa, Nobuyuki
[J]. ANTICANCER RESEARCH, 2024, 44 (04) : 1751 - 1757
[34] ASTRIS: A real world treatment study of osimertinib in patients (pts) with EGFR T790M positive non-small cell lung cancer (NSCLC).
De Marinis, Filippo
Cho, Byoung Chul
Kim, Dong-Wan
Kim, Sang-We
Hochmair, Maximilian J.
Metro, Giulio
Vansteenkiste, Johan F.
Vicente, David
Solomon, Benjamin J.
Cheema, Parneet K.
Freitas, Helano C.
Provencio, Mariano
Chen, Yuh-Min
Wu, Yi-Long
Milner, Alvin
Rigas, James R.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[35] Osimertinib for the treatment of non-small cell lung cancer
Sun, Jong-Mu
Lee, Se-Hoon
Ahn, Jin Seok
Park, Keunchil
Ahn, Myung-Ju
[J]. EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (02) : 225 - 231
[36] Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC)
Paulina Bracht, Jillian Wilhelmina
Karachaliou, Niki
Berenguer, Jordi
Pedraz-Valdunciel, Carlos
Filipska, Martyna
Codony-Servat, Carles
Codony-Servat, Jordi
Rosell, Rafael
[J]. INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES, 2019, 15 (12): : 2607 - 2614
[37] Recent Insights into Osimertinib Analogues against EGFR Positive Non-small Cell Lung Cancer
Chhabra, Jatin
Kashyap, Priyanka
Pahwa, Rakesh
Narang, Rakesh
Dureja, Harish
Lal, Sukhbir
Verma, Sangeeta
[J]. CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2023, 23 (21) : 2001 - 2026
[38] Osimertinib for treating Patients with EGFR Mutation-Positive non-small cell Lung Cancer
Meinrenken, Susanne
[J]. PNEUMOLOGIE, 2018, 72 (04): : 246 - 246
[39] ctDNA assessment of EGFR mutation status in Chinese patients with advanced non-small cell lung cancer in real-world setting
Zhang, Shirong
Zhu, Lucheng
Chen, Xueqin
Zhang, Xiaochen
Chen, Enguo
Fang, Hongming
Feng, Yuejuan
Li, Yuping
Wang, Xi
Jiang, Zhongyu
Wang, Yina
Zhang, Zhihao
He, Huijuan
Ma, Shenglin
[J]. JOURNAL OF THORACIC DISEASE, 2018, 10 (07) : 4169 - +
[40] Impact of Maintenance Therapy for Patients with Non-small Cell Lung Cancer in a Real-world Setting
Yoh, Kiyotaka
Goto, Yasushi
Naito, Yoichi
Kishi, Kazuma
Mori, Kiyoshi
Hotta, Katsuyuki
Hosomi, Yukio
Yamada, Kazuhiko
Tanai, Chiharu
Tomizawa, Yoshio
Inoue, Akira
Hasegawa, Yoshinori
Nishio, Makoto
Ohashi, Yasuo
Kunitoh, Hideo
[J]. ANTICANCER RESEARCH, 2017, 37 (03) : 1507 - 1513

← 1 2 3 4 5 →